Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2026)

Crinetics Pharmaceuticals' Retained Earnings history runs 10 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 77286.41% year-over-year to -$1.5 billion in Q1 2026; TTM through Mar 2026 was -$1.5 billion, a 77286.41% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, down 48.87% from the prior year.
• Retained Earnings eased to -$1.5 billion in Q1 2026 per CRNX's latest filing, from -$1.4 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $2.0 million in Q1 2025 and bottomed at -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$2.5 million (2023), against an average of -$427.6 million.
• Across the five-year window, Retained Earnings sank 3523100.0% in 2022 and surged 1234.67% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$439.2 million in 2022, then surged by 100.22% to $977000.0 in 2023, then plunged by 97552.41% to -$952.1 million in 2024, then sank by 48.87% to -$1.4 billion in 2025, then declined by 9.02% to -$1.5 billion in 2026.
• Per Business Quant, the three latest CRNX Retained Earnings figures stand at -$1.5 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.3 billion (Q3 2025).